OpenUCT :: Browsing by Subject "rBCG Vaccine"

Now showing 1 - 2 of 2

Open Access
P19-53 LB. Priming with recombinant BCG expressing HIV-1 Gag or RT and boosting with recombinant MVA induces an effective immune response in mice
(BioMed Central Ltd, 2009) Stutz, H; Powles, R; Shephard, EG; Williamson, A
Mycobacterium bovis BCG (BCG) has a number of characteristics that give it great potential to act as a vehicle for the delivery of recombinant vaccines. However, its success depends on overcoming the challenges of poor antigen expression levels and genetic instability. Our studies using an optimized mycobacterial shuttle vector which utilizes the Mycobacterium tuberculosis mtrA promoter, induced upon infection of macrophages, and the M. tuberculosis 19 kDa signal sequence may overcome these issues. We have used this system to generate a recombinant BCG (rBCG) expressing HIV-1 subtype C full length Gag or reverse transcriptase (RT).
Open Access
A prime-boost immunization with rBCG expressing HIV-1 Gag, RT and gp120 and SAAVI MVA-C elicits immune responses in blood and MALT of rhesus macaques
(BioMed Central Ltd, 2012) Chege, GK; Chapman, R; Shephard, EG; Williamson, A
CG pantothenate auxtroph (ΔpanCD) is safer to use as a live vaccine vector than wild-type BCG. We constructed 3 recombinant BCGΔpanCD candidate vaccines expressing HIV-1 subtype C Gag, RT and Env (gp120). The current study investigated immune responses in rhesus macaques following a prime with a mixture of these rBCG vaccines and a boost with SAAVI MVA-C (MVA).